Table of Contents
Molecular Biology International
Volume 2012 (2012), Article ID 781305, 12 pages
http://dx.doi.org/10.1155/2012/781305
Review Article

Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1

Topical Microbicide and STI Research Department, ImQuest BioSciences, Inc., 7340 Executive Way, Suite R, Frederick, MD 21704, USA

Received 13 February 2012; Accepted 11 May 2012

Academic Editor: Gilda Tachedjian

Copyright © 2012 Karen W. Buckheit and Robert W. Buckheit Jr. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. J. Feldblum, A. Adeiga, R. Bakare et al., “SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria,” PloS ONE, vol. 3, no. 1, Article ID e1474, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Tao, C. Richards, and D. Hamer, “Short communication: enhancement of HIV infection by cellulose sulfate,” AIDS Research and Human Retroviruses, vol. 24, no. 7, pp. 925–929, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Van Damme, “Effective of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial,” The Lancet, vol. 360, no. 9338, pp. 971–977, 2002. View at Google Scholar · View at Scopus
  4. C. Herrera and R. J. Shattock, “Potential use of protease inhibitors as vaginal and colorectal microbicides,” Current HIV Research, vol. 10, no. 1, pp. 42–52, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. T. Triforiova, G. F. Doncel, and R. N. Fichorova, “Polyanionic microbicides modify toll-like receptor-mediated cervicovaginal immune responses7,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 4, pp. 1490–1500, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. McCormack, G. Ramjee, A. Kamali et al., “PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial,” The Lancet, vol. 376, no. 9749, pp. 1329–1337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. Q. A. Karim, S. S. Abdool Karim, J. A. Frohlich et al., “Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women,” Science, vol. 329, no. 5996, pp. 1168–1174, 2010. View at Google Scholar · View at Scopus
  8. MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women, http://www.mtnstopshiv.org/node/3909.
  9. Studies , http://www.mtnstopshiv.org/studies.
  10. R. W. Buckheit Jr., K. M. Watson, K. M. Morrow, and A. S. Ham, “Development of topical microbicides to prevent the sexual transmission of HIV,” Antiviral Research, vol. 85, no. 1, pp. 142–158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Lackman-Smith, C. Osterling, K. Luckenbaugh et al., “Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 5, pp. 1768–1781, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. L. Hillier, “The vaginal microbial ecosystem and resistance to HIV,” AIDS Research and Human Retroviruses, vol. 14, supplement 1, pp. S17–S21, 1998. View at Google Scholar · View at Scopus
  13. B. Moller and P. Kaspersen, “The acicidity of the vagina,” in Vaginitis and Vaginosis, B. Horowitz and P. Marc, Eds., Wiley-Liss, New York, NY, USA, 1991. View at Google Scholar
  14. A. M. Cole and A. L. Cole, “Antimicrobial polypeptides are key anti-hiv-1 effector molecules of cervicovaginal host defense,” American Journal of Reproductive Immunology, vol. 59, no. 1, pp. 27–34, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. L. Gallo, M. Murakami, T. Ohtake, and M. Zaiou, “Biology and clinical relevance of naturally occurring antimicrobial peptides,” Journal of Allergy and Clinical Immunology, vol. 110, no. 6, pp. 823–831, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. L. S. Martin, J. S. McDougal, and S. L. Loskoski, “Disinfection and inactivation of the human T lymphocytropic virus type III lymphadenopathy-associated virus,” Journal of Infectious Diseases, vol. 152, no. 2, pp. 400–403, 1985. View at Google Scholar · View at Scopus
  17. J. Ongradi, L. Ceccherini-Nelli, M. Pistello, S. Specter, and M. Bendinelli, “Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications,” AIDS Research and Human Retroviruses, vol. 6, no. 12, pp. 1433–1436, 1990. View at Google Scholar · View at Scopus
  18. S. E. Godfrey, B. Voeller, D. J. Anderson et al., “Heterosexual transmission of HIV,” Journal of the American Medical Association, vol. 267, no. 14, pp. 1917–1919, 1992. View at Google Scholar · View at Scopus
  19. M. E. Quiñones-Mateu, M. M. Lederman, Z. Feng et al., “Human epithelial β-defensins 2 and 3 inhibit HIV-1 replication,” AIDS, vol. 17, no. 16, pp. F39–F48, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Sun, C. M. Finnegan, T. Kish-Catalone et al., “Human β-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection,” Journal of Virology, vol. 79, no. 22, pp. 14318–14329, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. T. M. Schaefer, J. V. Fahey, J. A. Wright, and C. R. Wira, “Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly(I:C),” Journal of Immunology, vol. 174, no. 2, pp. 992–1002, 2005. View at Google Scholar · View at Scopus
  22. C. R. Wira, J. V. Fahey, M. Ghosh, M. V. Patel, D. K. Hickey, and D. O. Ochiel, “Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens,” American Journal of Reproductive Immunology, vol. 63, no. 6, pp. 544–565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. M. Wahl, T. B. McNeely, E. N. Janoff et al., “Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1,” Oral Diseases, vol. 3, supplement 1, pp. S64–S69, 1997. View at Google Scholar · View at Scopus
  24. M. Ghosh, J. V. Fahey, Z. Shen et al., “Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies,” PloS ONE, vol. 5, no. 6, Article ID e11366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. S. M. Iqbal, T. B. Ball, P. Levinson et al., “Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition,” AIDS, vol. 23, no. 13, pp. 1669–1677, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Levinson, R. Kaui, J. Kimani et al., “Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition,” AIDS, vol. 23, no. 3, pp. 309–317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. G. F. Shust, S. Cho, M. Kim et al., “Female genital tract secretions inhibit herpes simplex infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception,” American Journal of Reproductive Immunology, vol. 63, no. 5, p. 410, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. J. Keller, P. M. Mesquita, N. M. Torres et al., “Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials,” PloS ONE, vol. 5, no. 1, Article ID e8781, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. H. Henderson, G. M. Couchman, D. K. Walmer et al., “Optical imaging and analysis of human vaginal coating by drug delivery gels,” Contraception, vol. 75, no. 2, pp. 142–151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. C. W. Hendrix, E. J. Fuchs, K. J. MacUra et al., “Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates,” Clinical Pharmacology and Therapeutics, vol. 83, no. 1, pp. 97–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. R. F. Omar, S. Trottier, G. Brousseau, A. Lamarre, Alexandre Gagnon, and M. G. Bergeron, “Distribution of a vaginal gel (Invisible Condom) before, during and after simulated sexual intercourse and its persistence when delivered by two different vaginal applicators: a magnetic resonance imaging study,” Contraception, vol. 77, no. 6, pp. 447–455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. E. N. Dunmire, A. M. Plenys, and D. F. Katz, “Spectrophotometric analysis of molecular transport in gels,” Journal of Controlled Release, vol. 57, no. 2, pp. 127–140, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. P. M. Gorbach, L. E. Manhart, K. L. Hess, B. P. Stoner, D. H. Martin, and K. K. Holmes, “Anal intercourse among young heterosexuals in three sexually transmitted disease clinics in the united states,” Sexually Transmitted Diseases, vol. 36, no. 4, pp. 193–198, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. S. C. Kalichman, L. C. Simbayi, D. Cain, and S. Jooste, “Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa,” Sexually Transmitted Infections, vol. 85, no. 6, pp. 411–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. T. Haase, “Early events in sexual transmission of hiv and siv and opportunities for interventions,” Annual Review of Medicine, vol. 62, pp. 127–139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Kreutei and U. Wieland, “Human papillomavirus-associated diseases in HIV-infected men who have sex with men,” Current Opinion in Infectious Diseases, vol. 22, no. 2, pp. 109–114, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. S. Smith, S. Moses, M. G. Hudgens et al., “Increased risk of HIV acquisition among kenyan men with human papillomavirus infection,” Journal of Infectious Diseases, vol. 201, no. 11, pp. 1677–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. I. J. Pandya and J. Cohen, “The leukocytic reaction of the human uterine cervix to spermatozoa,” Fertility and Sterility, vol. 43, no. 3, pp. 417–421, 1985. View at Google Scholar · View at Scopus
  39. L. A. Thompson, C. L. R. Barratt, A. E. Bolton, and I. D. Cooke, “The leukocytic reaction of the human uterine cervix,” American Journal of Reproductive Immunology, vol. 28, no. 2, pp. 85–89, 1992. View at Google Scholar · View at Scopus
  40. G. F. Doncel, T. Joseph, and A. R. Thurman, “Role of Semen in HIV-1 Transmission: inhibitor or facilitator?” American Journal of Reproductive Immunology, vol. 65, no. 3, pp. 292–301, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. B. G. Ludman, “Human seminal plasma protein allergy: a diagnosis rarely considered,” Journal of Obstetric, Gynecologic, and Neonatal Nursing, vol. 28, no. 4, pp. 359–363, 1999. View at Google Scholar · View at Scopus
  42. S. K. Lai, K. Hida, S. Shukair et al., “Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus,” Journal of Virology, vol. 83, no. 21, pp. 11196–11200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. S. K. Lai, Y. Y. Wang, K. Hida, R. Cone, and J. Hanes, “Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 2, pp. 598–603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. J. A. Turpin, “Topical microbicides to prevent the transmission of HIV: formulation gaps and challenges,” Drug Delivery and Translational Research, vol. 1, no. 3, pp. 194–200, 2011. View at Google Scholar
  45. B. E. Lai, A. R. Geonnotti, M. G. DeSoto, D. C. Montefiori, and D. F. Katz, “Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro,” Antiviral Research, vol. 88, no. 2, pp. 143–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. B. E. Lai, M. H. Henderson, J. J. Peters, D. K. Walmer, and D. F. Katz, “Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels,” Biophysical Journal, vol. 97, no. 9, pp. 2379–2387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. N. A. Louissaint, E. J. Fuchs, R. P. Bakshi et al., “Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse,” Journal of Infectious Diseases, vol. 205, no. 5, pp. 725–732, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. D. M. Butler, W. Delport, S. L. K. Pond et al., “The origins of sexually transmitted HIV among men who have sex with men,” Science Translational Medicine, vol. 2, no. 18, Article ID 18re1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. R. J. Shattock and J. P. Moore, “Inhibiting sexual transmission of HIV-1 infection,” Nature Reviews, vol. 1, no. 1, pp. 25–34, 2003. View at Google Scholar · View at Scopus
  50. J. F. Salazar-Gonzalez, M. G. Salazar, B. F. Keele et al., “Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection,” Journal of Experimental Medicine, vol. 206, no. 6, pp. 1273–1289, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. G. F. Doncel and M. R. Clark, “Preclinical evaluation of anti-HIV microbicide products: new models and biomarkers,” Antiviral Research, vol. 88, supplement, pp. S10–S18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. D. L. Patton, Y. T. C. Sweeney, and K. J. Paul, “A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model,” Sexually Transmitted Diseases, vol. 36, no. 6, pp. 350–356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Saifuddin, “Intravaginal administration of 6% cellulose sulfate (CS) gel prevented systemic infection in rhesus macaques in a multiple dose R5/X4 SHIV vaginal challenge model,” in Microbicides 2008, New Delhi, India, 2008. View at Google Scholar
  54. U. M. Parikh, C. Dobard, S. Sharma et al., “Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine,” Journal of Virology, vol. 83, no. 20, pp. 10358–10365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. P. W. Denton, J. D. Estes, Z. Sun et al., “Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice,” PLoS Medicine, vol. 5, no. 1, Article ID e16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. Z. Sun, P. W. Denton, J. D. Estes et al., “Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1,” Journal of Experimental Medicine, vol. 204, no. 4, pp. 705–714, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. K. B. Collins, B. K. Patterson, G. J. Naus, D. V. Landers, and P. Gupta, “Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract,” Nature Medicine, vol. 6, no. 4, pp. 475–479, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. J. E. Cummins Jr., J. Guarner, L. Flowers et al., “Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 5, pp. 1770–1779, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Greenhead, P. Hayes, P. S. Watts, K. G. Laing, G. E. Griffin, and R. J. Shattock, “Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides,” Journal of Virology, vol. 74, no. 12, pp. 5577–5586, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. B. E. Beer, G. F. Doncel, F. C. Krebs et al., “In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 2, pp. 713–723, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Niruthisard, R. E. Roddy, and S. Chutivongse, “The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa,” Sexually Transmitted Diseases, vol. 18, no. 3, pp. 176–179, 1991. View at Google Scholar · View at Scopus
  62. K. H. Mayer, S. A. Karim, C. Kelly et al., “Safety and tolerability of vaginal PRO 2000 Gel in sexually active HIV-uninfected and abstinent HIV-infected women,” AIDS, vol. 17, no. 3, pp. 321–329, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. D. L. Patton, Y. T. C. Sweeney, L. K. Rabe, and S. L. Hillier, “Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model,” Sexually Transmitted Diseases, vol. 29, no. 10, pp. 581–587, 2002. View at Google Scholar · View at Scopus
  64. D. M. Phillips, C. L. Taylor, V. R. Zacharopoulos, and R. A. Maguire, “Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium,” Contraception, vol. 62, no. 3, pp. 149–154, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Van Damme, A. Profy, M. Laga et al., “A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women,” Sexually Transmitted Infections, vol. 76, no. 2, pp. 126–130, 2000. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Mahalingam, A. P. Simmons, S. R. Ugaonkar et al., “Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 4, pp. 1650–1660, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. L. C. Rohan, B. J. Moncla, R. P. Kunjara Na Ayudhya et al., “In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide,” PloS ONE, vol. 5, no. 2, Article ID e9310, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. P. M. M. Mesquita, N. Cheshenko, S. S. Wilson et al., “Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety,” Journal of Infectious Diseases, vol. 200, no. 4, pp. 599–608, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. K. M. Watson, C. E. Buckheit, and R. W. Buckheit Jr., “Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 8, pp. 2787–2796, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Balzarini, A. Karlsson, M. J. Perez-Perez, M. J. Camarasa, and E. De Clercq, “Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus,” Virology, vol. 196, no. 2, pp. 576–585, 1993. View at Publisher · View at Google Scholar · View at Scopus
  71. E. Greene, G. Batona, J. Hallad, S. Johnson, S. Neema, and E. E. Tolley, “Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India,” Culture, Health and Sexuality, vol. 12, no. 7, pp. 739–754, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. VOICE StudyDesign, http://www.niaid.nih.gov/news/qa/pages/voiceqa.aspx.
  73. NIH Discontinues Tenofovir Vaginal Gel in ‘VOICE’ HIV Prevention Study, 2011, http://www.nih.gov/news/health/nov2011/niaid-25.htm.
  74. S. H. Vermund and L. Van Damme, “HIV prevention in women: next steps,” Science, vol. 331, no. 6015, p. 284, 2011. View at Google Scholar · View at Scopus
  75. R. K. Malcolm, K.-L. Edwards, P. Kiser, J. Romano, and T. J. Smith, “Advances in microbicide vaginal rings,” Antiviral Research, vol. 88, supplement, pp. S30–S39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Nel, S. Smythe, K. Young et al., “Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 4, pp. 416–423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. T. Lane, A. Pettifor, S. Pascoe, A. Fiamma, and H. Rees, “Heterosexual anal intercourse increases risk of HIV infection among young South African men,” AIDS, vol. 20, no. 1, pp. 123–125, 2006. View at Google Scholar · View at Scopus
  78. I. McGowan, “Rectal microbicides: can we make them and will people use them?” AIDS and Behavior, vol. 15, supplement, pp. S66–S71, 2011. View at Google Scholar · View at Scopus
  79. K. M. Morrow and M. S. Ruiz, “Assessing microbicide acceptability: a comprehensive and integrated approach,” AIDS and Behavior, vol. 12, no. 2, pp. 272–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. D. L. Patton, Y. T. Cosgrove Sweeney, J. E. Balkus et al., “Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 5, pp. 1608–1615, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. S. R. Tabet, C. Surawicz, S. Horton et al., “Safety and toxicity of Nonoxynol-9 gel as a rectal microbicide,” Sexually Transmitted Diseases, vol. 26, no. 10, pp. 564–571, 1999. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Anton, R. Cranston, and A. Carballo-Dieguez, “RMP-02/MTN-006: a phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF,” in Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections, Boston, Mass, USA, February 2011.
  83. L. Wang, R. L. Schnaare, C. Dezzutti, P. A. Anton, and L. C. Rohan, “Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulations,” AIDS Research and Therapy, vol. 8, article 12, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Dezzutti, “TFV Gel reformulation results in improved product safety for rectal application,” in Proceedings of the 18th Conference on Retroviruses and Opportunisitic Infections, Boston, Mass, USA, 2011.
  85. B. Y. Holt, M. Kilbourne-Brook, A. Stone, P. Harrison, and W. C. Shields, “Multipurpose prevention technologies for sexual and reproductive health: gaining momentum and promise,” Contraception, vol. 81, no. 3, pp. 177–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. D. R. Friend and G. F. Doncel, “Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: development of dual-protection technologies,” Antiviral Research, vol. 88, supplement, pp. S47–S54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. A. R. Thurman, M. R. Clark, and G. F. Doncel, “Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies,” Infectious Diseases in Obstetrics and Gynecology, vol. 2011, Article ID 429403, 10 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. D. L. Jones, S. M. Weiss, N. Chitalu et al., “Acceptability and use of sexual barrier products and lubricants among HIV-seropositive Zambian men,” AIDS Patient Care and STDs, vol. 22, no. 12, pp. 1015–1020, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Nath and S. Garg, “Microbicides in India-present and future,” Indian Journal of Medical Microbiology, vol. 27, no. 3, pp. 251–253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Bolton, A. van der Straten, and C. R. Cohen, “Probiotics: potential to prevent HIV and sexually transmitted infections in women,” Sexually Transmitted Diseases, vol. 35, no. 3, pp. 214–225, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. K. M. Morrow and C. Hendrix, “Clinical evaluation of microbicide formulations,” Antiviral Research, vol. 88, supplement, pp. S40–S46, 2010. View at Publisher · View at Google Scholar · View at Scopus